Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: A pilot prospective study

Digestion

Volumn 85, Issue 1, 2012, Pages 1-8

  Lahat, Adi ^a   Lang, Alon ^a   Shomron, Ben Horin ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cannabis; Crohn's disease; Disease activity; Inflammatory bowel disease; Quality of life; treatment; Ulcerative colitis; Weight gain

Indexed keywords

CANNABIS; PRESCRIPTION DRUG;

BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DEPRESSION; DISEASE ACTIVITY; ENTERITIS; FEMALE; HEALTH PERCEPTIONS QUESTIONNAIRE; HUMAN; MALE; PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; REVIEW; SOCIAL INTERACTION; ULCERATIVE COLITIS; WEIGHT GAIN; WORK CAPACITY;

ADMINISTRATION, INHALATION; ADULT; CANNABIS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MARIJUANA SMOKING; MIDDLE AGED; PAIN MEASUREMENT; PHYTOTHERAPY; PILOT PROJECTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 81155125103     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000332079     Document Type: Review

References (56)

1. Love JR, Irvine EJ, Fedorak RN: Quality of life in IBD. J Clin Gastroenterol 1992; 14: 15-19.
2. Casellas F, Arenas JI, Baudet JS, et al: Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005; 11: 488-496. (Pubitemid 40704084)
3. Rubin GP, Hungin AP, Chinn DJ, et al: Quality of life in patients with established inflammatory bowel disease: a UK general practice survey. Aliment Pharmacol Ther 2004; 19: 529-535. (Pubitemid 38387179)
4. Casellas F, López-Vivancos J, Badia X, et al: Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol 2001; 13: 567-572. (Pubitemid 32466261)
5. Canavan C, Abrams KR, Hawthorne B, et al: Long-term prognosis in Crohn's disease: factors that affect quality of life. Aliment Pharmacol Ther 2006; 23: 377-385. (Pubitemid 43382018)
6. Hjortswang H, Järnerot G, Curman B, et al: The influence of demographic and diseaserelated factors on health-related quality of life in patients with ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15: 1011-1020. (Pubitemid 37094302)
7. Gearry RB, Barclay ML, Burt MJ, et al: Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2004; 13: 563-567. (Pubitemid 39214035)
8. Fraser AG, Orchard TR, Jewell DP: The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30-year review. Gut 2002; 50: 485-489. (Pubitemid 34638866)
9. Colombel JF, Loftus EV Jr, Tremaine WJ, et al: The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31. (Pubitemid 38040720)
10. Schnitzler F, Fidder H, Ferrante M, et al: Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
11. Sandborn WJ, Loftus EV: Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 2004; 53: 780-782. (Pubitemid 38662124)
12. Lichtenstein GR, Feagan BG, Cohen RD, et al: Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-630.
13. Pertwee RG: Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-180. (Pubitemid 27337346)
14. Shook JE, Burks TF: Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 1989; 249: 444-449. (Pubitemid 19144833)
15. Izzo AA, Mascolo N, Pinto L, et al: The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol 1999; 384: 37-42.
16. Landi M, Croci T, Rinaldi-Carmona M, et al: Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors. Eur J Pharmacol 2002; 450: 77-83.
17. Hornby PJ, Prouty SM: Involvement of cannabinoid receptors in gut motility and visceral perception. Br J Pharmacol 2004; 141: 1335-1345. (Pubitemid 38638823)
18. Stander S, Schmelz M, Metze D, Luger T, Rukwied R: Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 2005; 38: 177-188. (Pubitemid 40779571)
19. Klein TW: Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005; 5: 400-411. (Pubitemid 40685989)
20. Klein TW, Newton C, Larsen K: The cannabinoid system and immune modulation. J Leukoc Biol 2003; 74: 486-496. (Pubitemid 38040375)
21. Samson MT, Small-Howard A, Shimoda LM, et al: Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 2003; 170: 4953-4962. (Pubitemid 36554724)
22. Yuan M, Kiertscher SM, Cheng Q, et al: Delta 9-tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol 2002; 133: 124-131. (Pubitemid 35346734)
23. Klein TW, Newton C, Larsen K, et al: Cannabinoid receptors and T helper cells. J Neuroimmunol 2004; 147: 91-94. (Pubitemid 38114954)
24. Facchinetti F, Del Giudice E, Furegato S, et al: Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lipopolysaccharide. Glia 2003; 41: 161-168. (Pubitemid 36262193)
25. Abel EL: Cannabis: effects on hunger and thirst. Behav Biol 1975; 15: 255-281.
26. Berry EM, Mechoulam R: Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 2002; 95: 185-190. (Pubitemid 35232136)
27. Di Marzo V, Matias I: Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585-589. (Pubitemid 40594198)
28. Kirkham TC: Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol 2005; 16: 297-313. (Pubitemid 41404803)
29. Sharkey KA, Pittman QJ: Central and peripheral signaling mechanisms involved in endocannabinoid regulation of feeding: a perspective on the munchies. Sci STKE 2005; 277: 15.
30. Pagotto U, Marsicano G, Cota D, et al: The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27: 73-100. (Pubitemid 43228239)
31. Harvey R, Bradshaw J: A simple index of Crohn's disease activity. Lancet 1980;i:514.
32. Lewis JD, Chuai S, Nessel L, et al: Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008; 14: 1660-1666.
33. Izzo AA ,Mascolo N, Tonini M, et al: Modulation of peristalsis by cannabinoid CB 1 ligands in the isolated guinea pig ileum. Br J Pharmacol 2000; 129: 984-990. (Pubitemid 30142912)
34. Heinemann A, Shahbazian A, Holzer P: Cannabinoid inhibition of guinea pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways. Neuropharmacology 1999; 38: 1289-1297. (Pubitemid 29333144)
35. Shook JE, Burks TF: Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 1989; 249: 444-449. (Pubitemid 19144833)
36. 9 -tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB 1 receptors. Eur J Pharmacol 1999; 371: 187-196. (Pubitemid 29217001)
37. Coruzzi G, Adami M, Coppelli G, et al: Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat. Naunyn Schmiedebergs Arch Pharmacol 1999; 360: 715-718. (Pubitemid 30012473)
38. Nalin DR, Rhead J, Rennels M, et al: Cannabis, hypochlorhydria and cholera. Lancet 1978;ii:859-862.
39. Mechoulam R: The pharmacohistory of Cannabis sativa; in Mechoulam R (ed): Cannabinoids as Therapeutic Agents. Boca Raton, CRC Press, 1986, pp 1-19.
40. Izzo AA, Fezza F, Capasso R, et al: Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001; 134: 563-570. (Pubitemid 32977900)
41. Mathison R, Ho W, Pittman QJ, et al: Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol 2004; 142: 1247-1254. (Pubitemid 39178878)
42. Kimball ES, Schneider CR, Wallace NH, et al: Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 2006; 291:G364-G371. (Pubitemid 44024696)
43. Richardson JD, Aanonsen L, Hargreaves KM: Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 1998; 345: 145-153. (Pubitemid 28212345)
44. Siegling A, Hofmann HA, Denzer D, et al: Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 2001; 415:R5-R7. (Pubitemid 32197627)
45. Sanson M, Bueno L, Fioramonti J: Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil 2006; 18: 949-956. (Pubitemid 44358865)
46. Hillsley K, McCaul C, Aerssens J, et al: Activation of the cannabinoid 2 (CB2) receptor inhibits murine mesenteric afferent nerve activity. Neurogastroenterol Motil 2007; 19: 769-777. (Pubitemid 47312400)
47. Lynn AB, Herkenham M: Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 1994; 268: 1612-1623. (Pubitemid 24100385)
48. Kulkarni-Narla A, Brown DR: Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res 2000; 302: 73-80.
49. Roth MD, Baldwin GC, Tashkin DP: Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. Chem Phys Lipids 2002; 121: 229-239. (Pubitemid 36044554)
50. Chang YH, Lee ST, Lin WW: Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J Cell Biochem 2001; 81: 715-723. (Pubitemid 32417096)
51. Facchinetti F, Del Giudice E, Furegato S, et al: Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lipopolysaccharide. Glia 2003; 41: 161-168. (Pubitemid 36262193)
52. Small-Howard AL, Shimoda LM, Adra CN, et al: Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells. Biochem J 2005; 388: 465-473. (Pubitemid 40839923)
53. Vannacci A, Passani MB, Pierpaoli S, et al: Nitric oxide modulates the inhibitory effect of cannabinoids on the immunological activation of guinea pig mast cells. Inflamm Res 2003; 52(suppl 1):S7-S8.
54. Pacher P, Batkai S, Kunos G: The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462. (Pubitemid 44394908)
55. Jamshidi N, Taylor DA: Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001; 134: 1151-1154. (Pubitemid 33097243)
56. Lynch ME, Young J, Clark AJ: A case series of patients using medicinal marihuana for management of chronic pain under the Canadian Marihuana Medical Access Regulations. J Pain Symptom Manage 2006; 32: 497-501. (Pubitemid 44755111)